BenzingaOctober 19, 2026 at 2:08 AM NY8 Days Ago
Gilead Announces Emvistegrast 200 Mg Met Primary Endpoint In Phase 2 Swift Dose-Ranging Study; Demonstrated Significant Differences Across Multiple Secondary Measures Of Disease Activity Based On Nominal P-Values; Plans To Initiate Phase 3 Emvistegrast Monotherapy Study In 2027
– Reuters
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
